AstraZeneca: Calquence helps control leukaemia

(CercleFinance.com) - AstraZeneca's Calquence significantly improved progression-free survival compared to chemo-immunotherapy in patients with previously untreated chronic lymphocytic leukaemia, the drugmaker said.


At the median follow-up of 28 months of the phase III trial, Calquence, in combination with obinutuzumab or as a monotherapy, cut the risk of disease progression or death by 90% and 80%, respectively, compared to chlorambucil plus obinutuzumab, the group said.

The trial also showed that 87% of patients on Calquence alone remained free of disease progression or death at 24 months.

These results were presented at the 2019 American Society of Hematology Annual Meeting in Orlando, Florida.

Copyright (c) 2019 CercleFinance.com. All rights reserved.